ENDRA Life Sciences Inc. (NASDAQ:NDRA – Get Free Report) was the target of a large decrease in short interest in May. As of May 29th, there was short interest totaling 19,820 shares, a decrease of 39.2% from the May 14th total of 32,603 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 18,084 shares, the short-interest ratio is currently 1.1 days.
Institutional Investors Weigh In On ENDRA Life Sciences
An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA – Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises about 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest position. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. 1.19% of the stock is owned by institutional investors and hedge funds.
ENDRA Life Sciences Stock Up 6.4%
Shares of NDRA traded up $0.29 on Monday, reaching $4.85. The stock had a trading volume of 28,467 shares, compared to its average volume of 69,106. The firm has a market capitalization of $6.16 million, a PE ratio of -0.60 and a beta of -0.04. The firm has a 50-day moving average of $5.11 and a 200 day moving average of $4.66. ENDRA Life Sciences has a twelve month low of $2.96 and a twelve month high of $11.96.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on NDRA shares. Ascendiant Capital Markets lowered their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ENDRA Life Sciences has a consensus rating of “Hold” and a consensus price target of $25.00.
View Our Latest Report on NDRA
ENDRA Life Sciences Company Profile
ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.
ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.
Featured Articles
- Five stocks we like better than ENDRA Life Sciences
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
